Washington—In a trial that treated a variety of advanced solid tumors with a targeted HER2 inhibitor, the objective response rate (ORR) was highly variable, although all patients enrolled had documented HER2 mutations.
The variability in response was traced to differences in HER2 mutation variations, but tumor lineage also seemed important. The trial offers evidence that targeting a common driver mutation across cancer types may be far more complex than initially predicted and hoped.
